Nektar Therapeutics Cost of Revenue
Nektar Therapeutics (NKTR) reported Cost of Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-03-13
- Nektar Therapeutics cost of goods and services sold for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics cost of goods and services sold for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics cost of goods and services sold for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics cost of goods and services sold for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics cost of goods and services sold for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Nektar Therapeutics cost of goods and services sold for fiscal 2024 was $30.69M, a 9.13% decline from fiscal 2023.
- Nektar Therapeutics cost of goods and services sold for fiscal 2023 was $33.77M, a 56.08% increase from fiscal 2022.
- Nektar Therapeutics cost of goods and services sold for fiscal 2022 was $21.64M, a 13.10% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-13 | $0.00 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $7.98M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $7.98M derived: sum of 3 quarters · filed 2026-03-13 | $12.41M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | $7.98M derived: sum of 2 quarters · filed 2026-03-13 | $12.41M derived: sum of 3 quarters · filed 2026-03-13 | $22.15M derived: sum of 4 quarters · filed 2026-03-13 |
| 2024-12-31 | $7.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $12.41M derived: sum of 2 quarters · filed 2026-03-13 | $22.15M derived: sum of 3 quarters · filed 2026-03-13 | $30.69M 10-K · filed 2026-03-13 |
| 2024-09-30 | $4.43M 10-Q · filed 2025-11-07 | $14.18M derived: sum of 2 quarters · filed 2025-11-07 | $22.71M 10-Q · filed 2025-11-07 | $29.99M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $9.74M 10-Q · filed 2025-08-08 | $18.27M 10-Q · filed 2025-08-08 | $25.56M derived: sum of 3 quarters · filed 2025-08-08 | $37.99M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $8.53M 10-Q · filed 2025-05-09 | $15.82M derived: sum of 2 quarters · filed 2025-05-09 | $28.25M derived: sum of 3 quarters · filed 2025-05-09 | $35.24M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $19.71M derived: sum of 2 quarters · filed 2025-03-14 | $26.71M derived: sum of 3 quarters · filed 2025-03-14 | $33.77M 10-K · filed 2025-03-14 |
| 2023-09-30 | $12.43M 10-Q · filed 2024-11-08 | $19.43M derived: sum of 2 quarters · filed 2024-11-08 | $26.48M 10-Q · filed 2024-11-08 | $32.72M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $6.99M 10-Q · filed 2024-08-09 | $14.05M 10-Q · filed 2024-08-09 | $20.29M derived: sum of 3 quarters · filed 2024-08-09 | $25.26M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $7.06M 10-Q · filed 2024-05-10 | $13.29M derived: sum of 2 quarters · filed 2024-05-10 | $18.27M derived: sum of 3 quarters · filed 2024-05-10 | $23.38M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $11.21M derived: sum of 2 quarters · filed 2024-03-05 | $16.32M derived: sum of 3 quarters · filed 2024-03-05 | $21.64M 10-K · filed 2024-03-05 |
| 2022-09-30 | $4.97M 10-Q · filed 2023-11-08 | $10.09M derived: sum of 2 quarters · filed 2023-11-08 | $15.40M 10-Q · filed 2023-11-08 | $21.57M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $5.12M 10-Q · filed 2023-08-09 | $10.43M 10-Q · filed 2023-08-09 | $16.59M derived: sum of 3 quarters · filed 2023-08-09 | $21.90M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $5.32M 10-Q · filed 2023-05-10 | $11.48M derived: sum of 2 quarters · filed 2023-05-10 | $16.79M derived: sum of 3 quarters · filed 2023-05-10 | $24.46M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $6.16M 10-K · filed 2022-03-01 | $11.47M derived: sum of 2 quarters · filed 2022-11-04 | $19.14M derived: sum of 3 quarters · filed 2022-11-04 | $24.90M 10-K · filed 2024-03-05 |
| 2021-09-30 | $5.31M 10-Q · filed 2022-11-04 | $12.98M derived: sum of 2 quarters · filed 2022-11-04 | $18.73M 10-Q · filed 2022-11-04 | $23.06M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $7.67M 10-Q · filed 2022-08-05 | $13.42M 10-Q · filed 2022-08-05 | $17.75M derived: sum of 3 quarters · filed 2022-08-05 | $23.32M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $5.76M 10-Q · filed 2022-05-06 | $10.08M derived: sum of 2 quarters · filed 2022-05-06 | $15.65M derived: sum of 3 quarters · filed 2022-05-06 | $21.42M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $4.32M 10-K · filed 2022-03-01 | $9.89M derived: sum of 2 quarters · filed 2022-03-01 | $15.67M derived: sum of 3 quarters · filed 2022-03-01 | $19.48M 10-K · filed 2023-02-28 |
| 2020-09-30 | $5.57M 10-K · filed 2022-03-01 | $11.34M derived: sum of 2 quarters · filed 2022-03-01 | $15.15M 10-Q · filed 2021-11-05 | $21.14M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $5.77M 10-K · filed 2022-03-01 | $9.58M 10-Q · filed 2021-08-06 | $15.57M derived: sum of 3 quarters · filed 2022-03-01 | $20.50M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.81M 10-K · filed 2022-03-01 | $9.80M derived: sum of 2 quarters · filed 2022-03-01 | $14.73M derived: sum of 3 quarters · filed 2022-03-01 | $19.75M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $5.99M 10-K · filed 2021-02-26 | $10.92M derived: sum of 2 quarters · filed 2021-02-26 | $15.93M derived: sum of 3 quarters · filed 2021-02-26 | $21.37M 10-K · filed 2022-03-01 |
| 2019-09-30 | $4.93M 10-K · filed 2021-02-26 | $9.95M derived: sum of 2 quarters · filed 2021-02-26 | $15.38M 10-Q · filed 2020-11-06 | $22.85M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $5.02M 10-K · filed 2021-02-26 | $10.46M 10-Q · filed 2020-08-07 | $17.92M derived: sum of 3 quarters · filed 2021-02-26 | $22.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $5.44M 10-K · filed 2021-02-26 | $12.90M derived: sum of 2 quarters · filed 2021-02-26 | $17.68M derived: sum of 3 quarters · filed 2021-02-26 | $23.21M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $7.46M 10-K · filed 2020-02-28 | $12.24M derived: sum of 2 quarters · filed 2020-02-28 | $17.77M derived: sum of 3 quarters · filed 2020-02-28 | $24.41M 10-K · filed 2021-02-26 |
| 2018-09-30 | $4.78M 10-K · filed 2020-02-28 | $10.30M derived: sum of 2 quarters · filed 2020-02-28 | $16.95M 10-Q · filed 2019-11-07 | $26.70M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $5.52M 10-K · filed 2020-02-28 | $12.17M 10-Q · filed 2019-08-09 | $21.92M derived: sum of 3 quarters · filed 2020-02-28 | $27.59M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $6.65M 10-K · filed 2020-02-28 | $16.40M derived: sum of 2 quarters · filed 2020-02-28 | $22.07M derived: sum of 3 quarters · filed 2020-02-28 | $31.06M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $9.75M 10-K · filed 2019-03-01 | $15.43M derived: sum of 2 quarters · filed 2019-03-01 | $24.42M derived: sum of 3 quarters · filed 2019-03-01 | $30.55M 10-K · filed 2020-02-28 |
| 2017-09-30 | $5.67M 10-K · filed 2019-03-01 | $14.66M derived: sum of 2 quarters · filed 2019-03-01 | $20.79M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2017-06-30 | $8.99M 10-K · filed 2019-03-01 | $15.12M derived: sum of 2 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $6.13M 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $30.21M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |